NCT05297617 - Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk | Biotech Hunter

Enrollment

696

Participants

Timeline

Start Date

October 12, 2022

Primary Completion Date

November 12, 2030

Study Completion Date

November 30, 2035

Conditions

Breast Cancer

Interventions

DRUG

Anti-aromatase inhibitor

"Treatment will be either:~* Letrozole, given per os, 2.5 mg daily~* Anastrozole, given per os, 1 mg daily~* Exemestane, given per os, 25 mg daily"

Trial Locations (2)

RECRUITING

Centre Hospitalier Universitaire de Limoges, Limoges

NOT_YET_RECRUITING

Institute Gustave Roussy, Villejuif